ArticleTopics in antiviral medicine2026
CROI 2026: Acute and Postacute COVID-19.
Article in Topics in antiviral medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) furthered our understanding of acute COVID-19, long COVID, postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viral immunity, and SARS-CoV-2 therapeutics. Results of a first-in-human validation study of DNA-encoded monoclonal antibody (DMAb) technology demonstrated safety and robust and durable monoclonal antibody (mAb) production, giving the green light to further develop the DMAb platform. Pemivibart administration to people with advanced HIV was well tolerated and associated with good levels of neutralizing antibodies. A new pan-coronavirus 3C-like protease inhibitor was shown to have similar pharmacokinetics and a similar safety profile in people with renal impairment and people with hepatic impairment. A study of SARS-CoV-2 infections in 2023 demonstrated continued risk for new incident diagnoses and worsening of prior comorbidities in the year after infection. SARS-CoV-2 infection in people with HIV is associated with discernible decline in estimated glomerular filtration rate in the 2 years after infection. A blinded study of circulating SARS-CoV-2 antigen found no association between the presence of antigen and the likelihood of having long COVID. Most people with long COVID in a cohort study have experienced stigma or feeling dismissed in interactions with their clinicians.
Indexed as
Identifiers
42127260PMC13345724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.